by @dministrator | Oct 27, 2022 | Vyluma
Preliminary data from landmark, three-year, international study demonstrate safety and efficacy of NVK002 as a potential treatment for the progression of myopia in children Bridgewater, NJ – October 27, 2022 – Vyluma, Inc (“Vyluma”), a biopharmaceutical...
by @dministrator | Sep 1, 2022 | Vyluma
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia Bridgewater, NJ – September 1, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company...
by @dministrator | Jun 14, 2022 | Vyluma
Bridgewater, NJ, USA, June 14, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an...
by @dministrator | May 2, 2022 | NevakarInjectables
Bridgewater, NJ, May 2, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced...
by @dministrator | Apr 28, 2022 | NevakarInjectables
Bridgewater, NJ, USA, April 28, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced...
Recent Comments